Assenagon Asset Management S.A. Grows Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Assenagon Asset Management S.A. raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 149.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 186,179 shares of the specialty pharmaceutical company's stock after buying an additional 111,613 shares during the period. Assenagon Asset Management S.A. owned about 0.89% of ANI Pharmaceuticals worth $11,107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Millennium Management LLC boosted its stake in shares of ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock valued at $14,651,000 after purchasing an additional 209,272 shares in the last quarter. American Century Companies Inc. grew its stake in shares of ANI Pharmaceuticals by 99.2% during the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company's stock valued at $6,357,000 after buying an additional 49,717 shares during the last quarter. Lisanti Capital Growth LLC purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth about $2,218,000. Hussman Strategic Advisors Inc. bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at about $2,178,000. Finally, Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock valued at $40,132,000 after acquiring an additional 21,053 shares during the period. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Stock Down 0.6 %

ANI Pharmaceuticals stock traded down $0.35 during trading hours on Monday, hitting $57.97. 191,280 shares of the stock traded hands, compared to its average volume of 212,067. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The firm's 50-day moving average price is $59.37 and its two-hundred day moving average price is $61.96. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. The company has a market cap of $1.22 billion, a PE ratio of 36.23 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The company had revenue of $138.00 million for the quarter, compared to analysts' expectations of $129.09 million. During the same period in the prior year, the firm earned $1.06 earnings per share. The firm's revenue for the quarter was up 18.5% on a year-over-year basis. On average, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ANIP. Truist Financial increased their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They issued an "overweight" rating and a $68.00 price target on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a report on Wednesday, September 18th. Finally, HC Wainwright restated a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, ANI Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $77.33.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.